Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2009 2
2010 2
2011 4
2012 2
2013 4
2014 10
2015 7
2016 9
2017 13
2018 10
2019 10
2020 12
2021 7
Text availability
Article attribute
Article type
Publication date

Search Results

85 results
Results by year
Filters applied: . Clear all
Page 1
Compare and contrast: pediatric cancer versus adult malignancies.
Kattner P, Strobel H, Khoshnevis N, Grunert M, Bartholomae S, Pruss M, Fitzel R, Halatsch ME, Schilberg K, Siegelin MD, Peraud A, Karpel-Massler G, Westhoff MA, Debatin KM. Kattner P, et al. Among authors: karpel massler g. Cancer Metastasis Rev. 2019 Dec;38(4):673-682. doi: 10.1007/s10555-019-09836-y. Cancer Metastasis Rev. 2019. PMID: 31832830 Review.
Novel IDH1-Targeted Glioma Therapies.
Karpel-Massler G, Nguyen TTT, Shang E, Siegelin MD. Karpel-Massler G, et al. CNS Drugs. 2019 Dec;33(12):1155-1166. doi: 10.1007/s40263-019-00684-6. CNS Drugs. 2019. PMID: 31768950 Free PMC article.
MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma.
Zhang Y, Nguyen TTT, Shang E, Mela A, Humala N, Mahajan A, Zhao J, Shu C, Torrini C, Sanchez-Quintero MJ, Kleiner G, Bianchetti E, Westhoff MA, Quinzii CM, Karpel-Massler G, Bruce JN, Canoll P, Siegelin MD. Zhang Y, et al. Among authors: karpel massler g. Cancer Res. 2020 Jan 1;80(1):30-43. doi: 10.1158/0008-5472.CAN-19-1389. Epub 2019 Nov 6. Cancer Res. 2020. PMID: 31694905 Free PMC article.
HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models.
Nguyen TTT, Zhang Y, Shang E, Shu C, Torrini C, Zhao J, Bianchetti E, Mela A, Humala N, Mahajan A, Harmanci AO, Lei Z, Maienschein-Cline M, Quinzii CM, Westhoff MA, Karpel-Massler G, Bruce JN, Canoll P, Siegelin MD. Nguyen TTT, et al. Among authors: karpel massler g. J Clin Invest. 2020 Jul 1;130(7):3699-3716. doi: 10.1172/JCI129049. J Clin Invest. 2020. PMID: 32315286 Free PMC article.
Considering the Experimental use of Temozolomide in Glioblastoma Research.
Herbener VJ, Burster T, Goreth A, Pruss M, von Bandemer H, Baisch T, Fitzel R, Siegelin MD, Karpel-Massler G, Debatin KM, Westhoff MA, Strobel H. Herbener VJ, et al. Among authors: karpel massler g. Biomedicines. 2020 Jun 4;8(6):151. doi: 10.3390/biomedicines8060151. Biomedicines. 2020. PMID: 32512726 Free PMC article. Review.
Cell death-based treatment of childhood cancer.
Westhoff MA, Marschall N, Grunert M, Karpel-Massler G, Burdach S, Debatin KM. Westhoff MA, et al. Among authors: karpel massler g. Cell Death Dis. 2018 Jan 25;9(2):116. doi: 10.1038/s41419-017-0062-z. Cell Death Dis. 2018. PMID: 29371599 Free PMC article. Review.
BET-inhibitors as sensitizers for BH3-mimetics.
Ishida CT, Karpel-Massler G, Siegelin MD. Ishida CT, et al. Among authors: karpel massler g. Aging (Albany NY). 2017 Jun 26;9(6):1475-1476. doi: 10.18632/aging.101259. Aging (Albany NY). 2017. PMID: 28657545 Free PMC article. No abstract available.
The limitations of targeting MEK signalling in Glioblastoma therapy.
Selvasaravanan KD, Wiederspohn N, Hadzalic A, Strobel H, Payer C, Schuster A, Karpel-Massler G, Siegelin MD, Halatsch ME, Debatin KM, Westhoff MA. Selvasaravanan KD, et al. Among authors: karpel massler g. Sci Rep. 2020 May 4;10(1):7401. doi: 10.1038/s41598-020-64289-6. Sci Rep. 2020. PMID: 32366879 Free PMC article.
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy.
Strobel H, Baisch T, Fitzel R, Schilberg K, Siegelin MD, Karpel-Massler G, Debatin KM, Westhoff MA. Strobel H, et al. Among authors: karpel massler g. Biomedicines. 2019 Sep 9;7(3):69. doi: 10.3390/biomedicines7030069. Biomedicines. 2019. PMID: 31505812 Free PMC article. Review.
85 results